CEU 2026: Once-Weekly Insulin: Innovations for Less Intervention in Diabetes (EED26AW012)

Availability

On-Demand

Release on Oct 22, 2026 7:00 PM Central Daylight Time
Expires on Dec 31, 2026

Cost

$0.00

Credit Offered

1 AMA PRA Category 1 Credit

1 ABIM-MOC Point

1 Participation Credit

Course Description
Target Audience
Learning Objectives
Accreditation Statement
Disclosure Statement
Faculty Disclosures

This session will include a live, virtual symposium, including case-based discussion, focused on advancements in basal insulin therapy to address current clinical knowledge gaps.

This program is supported by an educational grant from Novo Nordisk.

The intended audience for this Clinical Endocrinology Update (CEU) 2026 live virtual Ancillary symposium is endocrinologists, physician associates, nurse practitioners, and allied healthcare professionals who specialize in the management of diabetes.

Compare the efficacy, safety, and clinical considerations of once weekly versus daily basal insulin therapies in the management of T2D.
Develop individualized T2D management plans using innovative, evidence-based insulin therapies.
Evaluate patient-specific factors to determine appropriate candidacy for once-weekly insulin therapy.
Synthesize hypoglycemia management strategies for patients on once-weekly insulins.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Rodolfo J. Galindo, MD: Abbott Diabetes Care (Consultant, Honorarium Recipient); Amgen Inc. (Consultant); Aztra Zeneca (Advisory Board); Bayer (Consultant); Boehringer Ingelheim (Clinical Trial Investigator, Consultant); Dexcom (Consultant); Eli Lilly & Company (Advisory Board, Consultant, Honorarium Recipient); Merck (Advisory Board, Consultant); Novo Nordisk (Advisory Board, Clinical Trial Investigator, Consultant); Pfizer Inc (Clinical Trial Investigator); Roche Pharmaceuticals (Clinical Trial Investigator).

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an educational grant from Novo Nordisk Inc.


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274